局限性前列腺癌的新型治疗方案——血管靶向光动力疗法

梁梦天; 周逢海

doi:10.13201/j.issn.1001-1420.2020.07.014

局限性前列腺癌的新型治疗方案——血管靶向光动力疗法

梁梦天,
周逢海^,

- 甘肃省人民医院泌尿外科二科(兰州, 730000)

详细信息

通讯作者: 周逢海,E-mail:zhoufengh@163.com

中图分类号: R737.25

收稿日期: 2019-11-28

New therapy for localized prostate cancer——vascular-targeted photodynamic therapy

LIANG Mengtian,
ZHOU Fenghai^,

- Department of Urology Ⅱ, Gansu Provincial Hospital, Lanzhou, 730000, China

More Information

Corresponding author: ZHOU Fenghai, E-mail: zhoufengh@163.com

Received Date: 28 November 2019

摘要

摘要: 血管靶向光动力疗法(vascular targeted photodynamic therapy,V-PDT)是一种针对局限性前列腺癌的新兴疗法。此法作为一种非手术治疗,可以在杀死前列腺癌细胞的同时,对健康组织不造成损伤。这种疗法需要将特定的光敏剂注射到血液中,然后再用激光将其激活从而摧毁前列腺的肿瘤组织。在去除了主病灶之后,对可能存在散发的肉眼不可见的微小癌巢亦能予以消灭,继而大大减小了肿瘤复发的机会。由于V-PDT具有的微创,低毒不良反应等特点,患者术后可实现快速康复,平均住院时间明显缩短。本文将近年来的V-PDT的应用进展以及在治疗中存在的问题进行综述。
- 光动力疗法 /
- 前列腺癌 /
- 微创性 /
- 光敏剂 /
- 血管靶向
Abstract: Vascular-targeted photodynamic therapy(V-PDT) is a new therapy for localized prostate cancer. As a non-surgical treatment, this method can kill prostate cancer cells without damaging the healthy tissues. This therapy involves injecting specific photosensitizers into the blood and then activating them with lasers to destroy the tumor tissue of the prostate. After removing the main lesion, the small nests that may be sporadic invisible to the naked eye can also be eliminated, which greatly reduces the chance of tumor recurrence. Because of minimal invasion and low toxic side effects of V-PDT therapy, patients can achieve rapid rehabilitation after operation, and the average length of stay is shortened. This article reviews the recent advances in the application of V-PDT as well as the existing problems in the treatment of localized prostate cancer.
- photodynamic therapy /
- prostate cancer /
- minimal invasion /
- photosensitizer /
- vascular-targeted

HTML全文

参考文献(22)

[1]	赵炎,梁杰,林英立,等.根治性前列腺切除术在盆腔淋巴结受侵及转移性前列腺癌中的应用及现状[J].临床泌尿外科杂志,2019,34(12):1009-1012.
[2]	Siegel R,Ma J,Zou Z,et al.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
[3]	周宇权,丁雪飞,徐嘉男,等.局限性前列腺癌患者治疗前血清睾酮水平与病理分级的研究[J].临床泌尿外科杂志,2019,34(9):673-682.
[4]	Marien A,Gill I,Ukimura O,et al.Target ablation--image-guided therapy in prostate cancer[J].Urol Oncol,2014,32(6):912-923.
[5]	Cooperberg MR.Long-term active surveillance for prostate cancer:answers and questions[J].J Clin Oncol,2015,33(3):238-240.
[6]	Wilt TJ,Brawer MK,Jones KM,et al.Radical prostatectomy versus observation for localized prostate cancer[J].N Engl J Med,2012,367(9):203-213.
[7]	罗游,付军生,王志平,等.临床局限性前列腺癌根治性切除与观察等待预后比较的Meta分析[J].中国男科学杂志,2014,28(12):19-25.
[8]	王颖,顾瑛.肿瘤靶向光动力疗法的临床研究与应用新进展[J].中国激光医学杂志,2017,26(5):279-287.
[9]	Abdel-Rahmène A,Seébastien V,Eric B,et al.Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer(CLIN1001 PCM301):an open-label,phase 3,randomised controlled trial[J].Lancet Oncol,2017,18:181-191.
[10]	Xiao Z,Owen RJ,Liu W,et al.Lipophilic photosensitizer administration via the prostate arteries forphotodynamic therapy of the canine prostate[J].Photodiagnosis Photodyn Ther,2010,7(2):106-114.
[11]	Resnick MJ,Koyama T,Fan KH,et al.Long-term functional outcomes after treatment for localized prostate cancer[J].N Engl J Med,2013,368(5):436-445.
[12]	Noweski A,Roosen A,Lebdai S,et al.Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11(Phase Ⅱ Trials)[J].Eur Urol Focus,2018,S2405456918300920.
[13]	Azzouzi AR,Lebdai S,Benzaghou F,et al.Vascular-targeted photodynamic therapy with TOOKAD1 Soluble in localized prostate cancer:standardization of the procedure[J].World J Urol,2015,33(7):937-944.
[14]	Chelly S,Maulaz P,Bigot P,et al.Sexual function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment[J].Eur Urol Suppl,2019,18(1):e623.
[15]	Wong TW,Wang YY,Sheu HM,et al.Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus[J].Antimicrob Agents Chemother,2005,49(3):895-902.
[16]	Foote CS.Mechanisms of photosensitized oxidation[J].Science,1968,162(3857):963-970.
[17]	韩晓博,郑英虹,杨力明,等.光敏剂在光动力治疗中的研究进展[J].上海大学学报,2017,23(2):169-178.
[18]	田泽丹,许川山,全学模,等.声敏剂与光敏剂的研究进展[J].临床超声医学杂志,2008,10(1):14-16.
[19]	Andrzej MB.Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer-clinician’s insight[J].World J Methodol,2016,6(1):65-76.
[20]	Godtman RA,Holmberg E,Khatami A,et al.Long-term results of active surveillance in the Goteborg randomized,population-based prostate cancer screening trial[J].Eur Urol,2016,70:760-766.
[21]	D’Amico AV.Personalizing the use of active surveillance as an initial approach for men with newly diagnosed prostate cancer[J].J Clin Oncol,2015,33:3365-3366.
[22]	Hurwitz LM,Cullen J,Kim DJ,et al.Longitudinal regret after treatment for low and intermediaterisk prostate cancer[J].Cancer,2017,123(21):4252-4258.